Compare IDEXX Laboratories, Inc. (IDXX) vs NetFlix Inc (NFLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs NetFlix Inc — how do they compare? IDEXX Laboratories, Inc. trades at $556.84 (market cap $44.48B), while NetFlix Inc trades at $67.59 (market cap $281.48B). The key difference: NetFlix Inc is far larger — about 6.3× IDEXX Laboratories, Inc.'s market cap, and IDEXX Laboratories, Inc. is trading nearer its 52-week high, NetFlix Inc nearer its low. Which is the better fit depends on your goals.
| IDXX | NFLX | |
|---|---|---|
Market Cap | $44.48B | $281.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $126.33 |
52-Week Low | $520.87 | $67.60 |
Enterprise Value | $45.38B | $286.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Netflix (NFLX) is trading at $68.95, down 7.26% over 24 hours and approaching its 52-week low. The stock shows bearish technical signals with oversold RSI levels, while fundamentals remain strong with Q1 2026 EPS beating expectations at $1.23 versus $0.763. Revenue grew to $45.18B in 2025 with a net income margin of 24.3%, though valuation ratios like P/E of 21.26 and P/S of 6.02 suggest moderate pricing. Recent news highlights stock declines despite business growth, with focus on advertising expansion and content performance.
The outlook for NFLX is mixed; strong earnings and ad-tier scalability offer upside, but technical weakness and competitive pressures pose risks. Analysts maintain a buy consensus with a $90.47 price target, implying significant potential appreciation. Key risks include market sentiment shifts and execution challenges in new revenue streams, requiring careful monitoring of quarterly results and subscriber trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →
